Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tarsus Pharmaceuticals (TARS) Income from Continuing Operations (2020 - 2025)

Tarsus Pharmaceuticals (TARS) has 6 years of Income from Continuing Operations data on record, last reported at 6240000.0 in Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 72.97% year-over-year to 6240000.0; the TTM value through Dec 2025 reached 64157000.0, up 43.43%, while the annual FY2025 figure was 66418000.0, 42.52% up from the prior year.
  • Income from Continuing Operations reached 6240000.0 in Q4 2025 per TARS's latest filing, up from 12683000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 10410000.0 in Q1 2021 and bottomed at 42461000.0 in Q4 2023.
  • Average Income from Continuing Operations over 5 years is 19393500.0, with a median of 21334000.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: soared 631.94% in 2021, then crashed 420.98% in 2023.
  • A 5-year view of Income from Continuing Operations shows it stood at 14490000.0 in 2021, then rose by 5.96% to 13626000.0 in 2022, then tumbled by 211.62% to 42461000.0 in 2023, then surged by 45.63% to 23086000.0 in 2024, then surged by 72.97% to 6240000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 6240000.0 in Q4 2025, 12683000.0 in Q3 2025, and 20195000.0 in Q2 2025.